📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). (2015)

First Author: Black DM

Attributed to: CIMA: The Centre for Integrated Research into Musculoskeletal Ageing funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1002/jbmr.2442

PubMed Identifier: 25545380

Publication URI: http://europepmc.org/abstract/MED/25545380

Type: Journal Article/Review

Volume: 30

Parent Publication: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Issue: 5

ISSN: 0884-0431